BioCentury
ARTICLE | Product Development

Jan. 14 Quick Takes: Pancreatic cancer data lifts NantKwest; plus NIH-Alkermes, Abbott, Inzen

January 15, 2021 2:38 AM UTC

NantKwest Inc. (NASDAQ:NK) rose $3.01 (20%) to $17.79 Thursday after announcing positive interim data from the Phase II QUILT 88 trial in metastatic pancreatic cancer. Early data showed that treatment with PD-L1 t-haNK therapy led to an 83% survival rate in 18 patients in the single-arm cohort C portion of the trial, which began enrolling patients in October. The PD-L1 t-haNK is an NK cell therapy that expresses a PD-L1 targeted CAR. 

Vivitrol combo effective in methamphetamine use disorder 
NIH reported data from the Phase III ADAPT-2 trial that a combination of Vivitrol naltrexone from Alkermes plc (NASDAQ:ALKS) and oral bupropion was effective in treating moderate or severe methamphetamine use disorder. The data were published in The New England Journal of Medicine. ...